Published in J Am Heart Assoc on August 26, 2014
Pharmacogenetics of Ace Inhibitor-Associated Angioedema | NCT01413542
DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res (2015) 0.93
Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition. Hypertension (2016) 0.75
Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies. Curr Opin Lipidol (2016) 0.75
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation (2008) 4.22
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab (2004) 3.65
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest (2002) 2.54
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab (2003) 2.41
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab (2007) 1.82
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept (2005) 1.56
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther (2007) 1.48
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin (2007) 1.43
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol (2011) 1.34
The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol (2004) 1.27
The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J (2010) 1.24
The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes. Diabetes Care (2011) 1.23
Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension (2012) 1.18
Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol (2006) 1.14
Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem (2005) 1.12
The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem (2003) 1.12
Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension (2002) 1.10
Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol (2008) 1.00
Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. Diabetes Care (2012) 0.99
Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am Heart J (1998) 0.97
Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. Hypertension (2014) 0.96
The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence. J Diabetes Res (2013) 0.87
An unsuspected property of natriuretic peptides: promotion of calcium-dependent catecholamine release via protein kinase G-mediated phosphodiesterase type 3 inhibition. Circulation (2011) 0.85
Vascular effects of natriuretic peptides in healthy men. J Cardiovasc Pharmacol Ther (2004) 0.79